Ziyaur Rahman

Associate Professor

Department of Pharmaceutical Sciences
Mail Stop 1114
159 Reynolds Medical Building
College Station, TX   77843

Phone: 979-845-2387
Fax: 979-436-0087
rahman@tamhsc.edu

Education and Training

B.S. in Pharmacy, Hamdard University, 2000

M.S. in Pharmaceutics, Hamdard University, New Delhi, India, 2002

Ph.D. in Pharmaceutics, Hamdard University, New Delhi, India, 2005

Postdoctoral Research Associate, School of Pharmacy, University of Mississippi, 2007-2008

ORISE Fellow, Division of Product Quality Research, CDER, FDA, Maryland, USA, 2008-2011

Teaching Interests

  • Process and product development
  • Industrial and physical pharmacy
  • Pharmaceutics compounding
  • Pharmaceutical calculation
  • Controlled and targeted drug delivery
  • Chemometric and big-data management

Research Interests

  • Formulation and process design of traditional (tablet, capsule, gel, emulsion, ointment etc) and complex dosage forms (microparticles, implant, pediatric, nanosuspension, nanoemulsion etc.);
  • Drug product quality and process understanding through Quality by Design (QbD) and Process Analytical Technologies (PAT) approaches;
  • Development of in vitro release performance tests for traditional and complex dosage forms
  • Evaluation of in-vitro bioequivalence for complex dosage forms
  • Design and evaluation of abuse-deterrent/meth-deterrent formulations
  • 3-dimensional printers’ application in pharmaceuticals printing
  • Continuous manufacturing of pharmaceutical dosage forms
  • Application of non-destructive methods (Raman, FTIR, XRPD, ssNMR, NIR, NIR-Chemical imaging) for quantification of components of formulations
  • Multivariate analysis (chemometrics, PCR, PLSR, DFA etc.) in pharmaceutics

Selected Publications

Follow the link for complete list of published work https://www.ncbi.nlm.nih.gov/sites/myncbi/1Rel7PAiLOIQN/bibliography/51788039/public/?sort=date&direction=ascending


National Service & Recongnition

  • FDA liaison to USP Expert Committee on Excipients, 2015-2016.  
  • Member of ‘Immediate Release/Modified Release Work Group’, Office of Pharmaceutical Quality, FDA, 2015
  • FDA grant reviewer, 2014-2016
  • Editorial board member of International Journal of Pharmaceutical Investigation, American Journal of Analytical chemistry, Current Nanoscience and Scientia Pharmaceutica
  • Reviewer for more than a dozen peer reviewed journals
  • FDA ‘Team Excellence’ award for ‘The development of a new in-vitro dissolution method to demonstrate bioequivalence of vancomycin hydrochloride to allow submission to ANDAs’ in 2010
  • Teaching Team’ award of the year 2012 for ‘Electrolyte, Acid-Bases and Nutrition’ course (IPT: PHAR 710). Texas A&M Health Science Center
  • FDA ‘Team Excellence’ award for ‘Cyclosporine Ophthalmic Research, in 2014
  • FDA ‘Regulatory Science Excellence’ award for ‘Chemometric Methods for Tacrolimus Crystallinity Team’ for the quantification of crystallinity and discriminatory dissolution methods development for the tacrolimus products’, in 2014
  • FDA ‘Team Excellence’ award for ‘The extraordinary contributions to the review and management of post approval changes to ANDAs’ in 2014.
  • FDA ‘Certificate of Appreciation’ for serving distinguished CDER faculty 2014-2015.
  • FDA Regulatory Science Excellence’ award for ‘Developing a performance matrix for equivalence evaluation of cyclosporine ophthalmic emulsions, paving the pathway for generic approval and provided scientific support to address sponsor’s CP request’ in 2015.
  • FDA ‘Team Excellence’ award for ‘Understanding the root cause of warfarin sodium product quality, development of discriminatory dissolution method and chemometric models for warfarin sodium fraction quantification’ in 2015
  • FDA ‘Special Recognition’ award for ‘The outstanding first review of generic abuse-deterrent formulations through a pilot review-research team approach’ in 2015
  • FDA ‘Special Recognition’ award for ‘Outstanding research effort on Abuse Deterrent Formulations and for the first review of generic ADF through a pilot Review-Research team approach’ in 2016
  • FDA ‘Team Excellence’ award for ‘Development of in-vitro quality metrics of acyclovir ointment and cream for the review of NDA # 20408 and Zovirax ANDAs’ in 2016
  • 'FDA group recognition’ award for ‘Crystalline quantification in new tacrolimus extended release product for regulatory action’ in 2016
  • FDA Regulatory Science Excellence’ award for ‘Quantification of crystalline fraction of warfarin sodium in the drug products and in-use stability of commercial products’ in 2016
  • 'FDA Leveraging Collaboration’ award for ‘Outstanding research effort on cyclosporine ophthalmic emulsion and for the precedent setting review of generics through a pilot review-research approach’ in 2016